Effect of KLF6 on prostate cancer cell line PC-3 by transgenic method.
- Author:
Ming SUN
1
;
Yu-ru YANG
;
Jian HUANG
;
Hong LI
;
Yi-ping LU
;
Qiang WEI
;
Tian-yong FAN
;
Xiang LI
Author Information
- Publication Type:Journal Article
- MeSH: Apoptosis; physiology; Cell Cycle; physiology; Cell Line, Tumor; Cyclin D1; biosynthesis; Down-Regulation; Flow Cytometry; Humans; Immunohistochemistry; Kruppel-Like Factor 6; Kruppel-Like Transcription Factors; genetics; physiology; Male; Prostatic Neoplasms; metabolism; pathology; Proto-Oncogene Proteins; genetics; physiology; Proto-Oncogene Proteins c-bcl-2; biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; Transfection
- From: National Journal of Andrology 2006;12(6):502-509
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the effect of KLF6 on prostate cancer cell line PC-3 by transgenic method.
METHODSWe obtained KLF6 cDNA by RT-PCR method from the liver cell, transfected plasmid pEGFP-C, recombinated with KLF6 into PC-3 cells, and used them as a transfection group and a control group. MTT, flow cytometer and immunocytochemical methods were used to observe the effect of anti-oncogene wild type KLF6 on prostate cancer cell line PC-3 by transgenic method for 48 hours.
RESULTSAfter transfected into PC-3 cells, KLF6 enhanced growth suppression, (30.0 +/- 5.4)% in the transfection group and 0% in the control, P < 0.01, apoptosis, (24.3 +/- 2.3)% in the transfection group and (5.2 +/- 0.7)% in the control, P < 0.01, the down-regulation of the expression of cyclin D1, (25.3 +/- 3.7)% in the transfection group and (38.5 +/- 4.6)% in the control, P < 0.05 and Bcl-2, (18.7 +/- 3.2)% in the transfection group, and (41.8 +/- 5.9)% in the control, P < 0.01 in PC-3 cells. It also decreased the ratio of the cell phase G2/M, increased the ratio of G0/G1 from (58.6 +/- 7.3)% in the control to (80.0 +/- 9.8)% in the transfection group, P < 0.05.
CONCLUSIONPC-3 cells transfected with wild type KLF6 can enhance its growth suppression and apoptosis. It shows great potential for the gene therapy of androgen-independent carcinoma of the prostate.
